List view / Grid view
16 June 2014 | By Novo Nordisk
Data from a new phase 3 study demonstrated that once-daily Victoza® (liraglutide) provided greater glycaemic control versus placebo with no worsening of renal function in adults with type 2 diabetes and moderate renal impairment...
16 June 2014 | By Novartis
Novartis announced that the US Food and Drug Administration licensed its manufacturing facility in Holly Springs, N.C. for the production of cell-culture influenza vaccines...
16 June 2014 | By GlaxoSmithKline
New data from secondary analyses of four randomised phase III studies being presented at the 74th Scientific Sessions of the American Diabetes Association...
16 June 2014 | By Biogen Idec
Biogen Idec and AbbVie announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority of once-monthly, subcutaneous daclizumab high-yield process...
16 June 2014 | By Freeman Technology
Freeman Technology, a global leader in powder characterisation, has published a new educational guide entitled ‘An Introduction to Powders’...
13 June 2014 | By B&W Tek, Inc.
B&W Tek has announced the enhanced TacticID handheld Raman spectrometer, featuring new functionality and safety...
12 June 2014 | By kdm communications
Syrris is pleased to announce the forthcoming launch of itsAsia Flux electrochemistry module at the International Conferences on MicroREaction Technology (IMRET) in Budapest...
12 June 2014 | By Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. presented positive results from a phase 3 trial of investigational drug sarilumab in rheumatoid arthritis patients who were inadequate responders to methotrexate therapy...
12 June 2014 | By GlaxoSmithKline
Agreement is ViiV Healthcare’s first external collaboration for development of a two drug single-tablet combining dolutegravir and rilpivirine...
12 June 2014 | By AstraZeneca
Phase IIa clinical study to commence in patients with severe asthma...
12 June 2014 | By Amgen
Phase 3 program underway to further assess Brodalumab as potential treatment for people living with psoriatic arthritis...
11 June 2014 | By Novo Nordisk
Up to 2022, Novo Nordisk expects to hire 6,000 new employees in Denmark, half of whom will work within research and development...
11 June 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that a R&D project for a novel, versatile vaccine adjuvant for the purpose of creating a novel vaccine has been awarded a “Newly extended Technology transfer Program”...
11 June 2014 | By AbbVie
AbbVie announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases...
11 June 2014 | By Pfizer
Additional data further characterizes the safety profile of XELJANZ...
